Advertisement

Topics

FDA expands J&J Zytiga combo's indication to include castration-sensitive prostate cancer

04:45 EST 9 Feb 2018 | Pharmafile

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC).

read more

Original Article: FDA expands J&J Zytiga combo's indication to include castration-sensitive prostate cancer

NEXT ARTICLE

More From BioPortfolio on "FDA expands J&J Zytiga combo's indication to include castration-sensitive prostate cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...